Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01
This study was registered at the University Hospital Medical Information Network Clinical Trials Registry on 9 March, 2023 (identification UMIN000050552).
Authors
- Tomoya Fukui (ORCID: https://orcid.org/0000-0003-4814-4401)
- Rai Shimoyama (ORCID: https://orcid.org/0000-0001-8601-0442)
- Masataka Taguri (ORCID: https://orcid.org/0000-0001-8902-0056)
- Yoshinori Imamura (ORCID: https://orcid.org/0000-0002-5202-531X)
- Kiyoaki Uryu (ORCID: https://orcid.org/0009-0008-6068-1385)
- Akihiko Iwase
- Yusuke Chihara (ORCID: https://orcid.org/0000-0002-7533-844X)
- Takafumi Okabe
- Makoto Hibino (ORCID: https://orcid.org/0000-0002-1638-5027)
- Yukihiro Tamura
- Ryuta Fukai (ORCID: https://orcid.org/0000-0001-8483-7788)
- Hironobu Minami (ORCID: https://orcid.org/0000-0001-8630-9145)
- T. Okuda (ORCID: https://orcid.org/0009-0005-1432-6938)
Institutions
- Tokyo Medical University (JP)
- Shonan Institute of Technology (JP)
- Kyoto University (JP)
- Fujisawa City Hospital (JP)
- National Institute of Fitness and Sports in Kanoya (JP)
- Kobe University Hospital (JP)
- Chiba-Nishi General Hospital (JP)
- Yao Tokushukai General Hospital (JP)
- Izumi City General Hospital (JP)
- Shonan Kamakura General Hospital (JP)
- Kishokai Medical Corporation (JP)
- Kobe University (JP)
Publication Details
- Journal
- Targeted Oncology
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1007/s11523-024-01094-5
- Citations
- 7
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 2.93
Funders
- JST-Mirai Program